Form 4: Revolution Medicines Executive Xiaolin Wang Reports Gift of Common Stock
SEC Form 4 Filing
Xiaolin Wang, EVP of Clinical Development at Revolution Medicines, reported a gift of 2,718 shares of common stock on March 17, 2025, leaving them with 102,321 shares.
Summary
- On March 19, 2025, a Form 4 filing was submitted to the SEC regarding Xiaolin Wang's beneficial ownership of Revolution Medicines, Inc. [RVMD] securities.
- The filing indicates that Xiaolin Wang, EVP, Clinical Development, gifted 2,718 shares of Common Stock on March 17, 2025.
- Following the transaction, Wang directly owns 102,321 shares of Common Stock, which includes 56,650 restricted stock units.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing reporting a transaction by an insider. It doesn't inherently convey positive or negative sentiment.
Industry Context
Form 4 filings are a routine part of the US equity market and are required by the SEC to provide transparency into the transactions of company insiders.
Stakeholder Impact
- The transaction may have a minor impact on shareholders due to the change in insider ownership.
Key Dates
| Date | Description |
|---|---|
| 03/17/2025 | Date of transaction: Gift of 2,718 shares of Common Stock. |
| 03/19/2025 | Date of Form 4 filing. |
Keywords
Form 4, Beneficial Ownership, Revolution Medicines, RVMD, Xiaolin Wang, Clinical Development, Stock Gift, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.